Needham & Company
-
Vericel to Present at the 22nd Annual Needham Growth Conference on Wednesday, January 15, 2020
-
Vericel to Present at Needham Healthcare Conference
-
Vericel to Present at Needham Healthcare Conference
-
Needham & Company Downgrades Vericel Corporation (VCEL) to Hold
-
Vericel to Present at the 21st Annual Needham Growth Conference
-
Vericel to Present at the 21st Annual Needham Growth Conference
-
Vericel Corporation (VCEL) PT Raised to $18 at Needham & Company
-
Vericel Corporation (VCEL) PT Lowered to $14 at Needham & Company, Keeps 'Buy'
-
Vericel to Present at the 17th Annual Needham Healthcare Conference
-
Pre-Open Movers 03/06: (AMDA) (CLBS) (GNCA) Higher; (GLYC) (FRPT) (ASNA) Lower (more...)
-
Vericel Corporation (VCEL) PT Raised to $15 at Needham & Company
-
Vericel to Present at the 20th Annual Needham Growth Conference
-
Vericel to Present at the 20th Annual Needham Growth Conference
-
Vericel to Present at the 16th Annual Needham Healthcare Conference
-
Vericel (VCEL) MACI Approval Puts Profitability Within Reach - Needham & Company
-
Vericel to Present at 15th Annual Needham Healthcare Conference
-
Needham & Company Maintains Bullish View on Vericel (VCEL) Following Ixmyelocel Data; Primary Endpoint 'Robust', Secondary 'Confounding'
-
Notable Analyst Rating Changes 3/11: (HTZ) (FNSR) (CVE) Upgraded; (WSM) (NGL) (SGY) Downgraded
-
Needham & Company Upgrades Vericel Corporation (VCEL) to Buy, $12 PT
-
Vericel to Present at Needham Healthcare Conference
-
Vericel to Present at Needham Healthcare Conference

